ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

HUGE FSD Pharma Inc

0.3483
-0.0157 (-4.31%)
After Hours
Last Updated: 21:32:31
Delayed by 15 minutes
Share Name Share Symbol Market Type
FSD Pharma Inc NASDAQ:HUGE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0157 -4.31% 0.3483 0.3622 0.37 0.375 0.34 0.36 391,990 21:32:31

GBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case

11/01/2024 6:10pm

GlobeNewswire Inc.


FSD Pharma (NASDAQ:HUGE)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more FSD Pharma Charts.

GBB Drink Lab. Inc (“GBB” or the “Company”), a maker of the world’s first rapid blood alcohol detoxification beverage, is pleased to announce that a federal court has refused to dismiss the Company’s ongoing lawsuit against FSD Pharma.

FSD Pharma (NASDAQ: HUGE), a clinical-stage biotech company, has violated a Non-Disclosure Agreement (NDA) with GBB and has breached the contract by attempting to steal information and launch GBB’s product without permission.

"Nowhere in the Amended Complaint does Plaintiff allege that all nineteen of the ingredients are necessary to create a parallel program or competitor drink, and this Court sees no reason to impose such a requirement. It is apparent, at least to this Court, that Plaintiff takes issue with Defendants’ development of a competing drink, which relies on most of the same ingredients (and methods for combining such ingredients) as Plaintiff’s proprietary beverage,” said the Court.

The Court added, “Drawing all inferences in Plaintiff’s favor, this Court concludes that Plaintiff has sufficiently demonstrated that its trade secrets derived economic value from not being readily ascertainable by others. Plaintiff alleges that the unidentified investors pulled out of the contemplated deals “because of Defendants’ announcements (and the promotional content) related to the development and planned future launch of a competing product that utilizes GBB’s confidential information.”

The Court’s decision not to dismiss the case represents a major victory for the Company and GBB is aggressively continuing legal action against the theft of their confidential information and to stop FSD Pharma from launching their product.

“The Court’s decision to not dismiss our case demonstrates that we have a strong legal position based on the facts. We look forward to a full and fair proceeding to resolve this matter and we believe that we will be victorious,” said GBB CEO John Gulyas.

About GBB Drink LabGBB Drink Lab started with a vision of making a positive impact by offering practical, evidence-based solution to reducing Blood Alcohol Content. The company’s product has been meticulously crafted to optimize your ability to reduce the effects of alcohol to escape an inebriated state. GBB Drink Lab leadership team includes accomplished serial entrepreneurs, a former senior executive from one of the world’s largest beverage companies, and an industry leading expert in flavoring science and product formulation.

Media Contact:

Phone: 602-456-1555 Email info@gbbdrinklab.com

1 Year FSD Pharma Chart

1 Year FSD Pharma Chart

1 Month FSD Pharma Chart

1 Month FSD Pharma Chart

Your Recent History

Delayed Upgrade Clock